Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | thyroid cancer |
| ICD-0-3 | C73.9 |
| Methods | qPCR |
| Sample | thyroid cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | There was a decrease in the lncRNA GAS5 expression in TC tissues in comparison to benign tumor tissues. Expression of lncRNA GAS5 showed significant association with tumor node metastasis (TNM) staging, lymph node metastasis and the multiple cancer foci of TC. The survival rate of TC patients with high lncRNA GAS5 expression was higher than that of TC patients with low lncRNA GAS5 expression during the DFS and OS periods. |
| Pubmed ID | 28506768 |
| Year | 2017 |
| Title | Low expression of long non-coding RNA GAS5 is associated with poor prognosis of patients with thyroid cancer |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for thyroid cancer | OMIM COSMIC |